Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review current treatment strategies and challenges for the management of myelofibrosis and the evolving treatment landscape of the disease.
EP. 1: Overview of Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.
EP. 2: Risk Stratification and Patient Classification for PMF
Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.
EP. 3: Treatment Strategies for Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.
EP. 4: Challenges in Myelofibrosis Treatment
Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.
EP. 5: Impact of Cytopenias on MF Treatment
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.
EP. 6: Monitoring Treatment Response in MF
Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.
EP. 7: Role of JAK-STAT Pathway in Myelofibrosis
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.
EP. 8: PERSIST-1 and PERSIST-2 Trials in Myelofibrosis
Expert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors